Reglan Tardive Dyskinesia Settlement: Claim Valuation Factors Overview

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

Legacy Context and Transition to Reglan Risk Assessment

The legacy domain has established a foundation in general health and science information, drawing on structured public data sources such as clinical trial registries and FDA databases to provide accessible overviews of medical topics. This heritage emphasizes clarity and neutrality, serving audiences seeking reliable entry points into complex health subjects. Within this framework, the transition now narrows focus to a specific therapeutic context: the use of Reglan (metoclopramide) and its associated risks. While general health information often covers broad drug categories and common side effects, a more targeted examination is warranted for substances with known long-term safety signals. In particular, occupational exposure scenarios—such as those encountered by healthcare workers administering the drug or pharmaceutical personnel handling its production—introduce distinct considerations. These settings may involve repeated or prolonged contact, differing from typical patient exposure patterns. The following discussion pivots from the general health context to address the specific concern of Reglan exposure in occupational environments, where the risk of tardive dyskinesia becomes a focal point for claim valuation. This shift maintains the domain’s commitment to data-driven analysis while honing in on a specialized area of safety assessment.

Find Out If You Qualify for Compensation →

Bridge: From General Safety to Specific Risk Factors

Building on the legacy of general health information, this section bridges to the specific risk factors associated with Reglan-induced tardive dyskinesia (TD). Reglan (metoclopramide) is associated with a risk of tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan, stating that the risk of developing TD increases with the duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning applies to all metoclopramide products, including Reglan tablets, and emphasizes that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need. For patients with symptomatic, documented gastroesophageal reflux, the maximum treatment duration is 12 weeks; for diabetic gastroparesis, treatment beyond 12 weeks should be avoided unless longer use is unavoidable, in which case routine monitoring for TD signs and symptoms is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Clinical Presentation and Mechanism of Tardive Dyskinesia

The clinical presentation of TD includes involuntary, often disfiguring movements of the face or tongue, and sometimes the trunk or extremities. Diagnosis is based on clinical evaluation, as there are no definitive laboratory tests. The condition can be masked by metoclopramide itself, which may suppress or partially suppress TD signs, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Mechanistically, metoclopramide acts as a dopamine D2 receptor antagonist in the central nervous system, a property shared with antipsychotic drugs known to cause TD. Chronic blockade of dopamine receptors is thought to lead to upregulation and supersensitivity of postsynaptic receptors, resulting in the hyperkinetic movements characteristic of TD. This pathway is supported by the drug's pharmacology and the observation that concomitant use of other drugs known to cause TD or extrapyramidal symptoms (EPS) should be avoided (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Epidemiological Evidence and Risk Factors

Epidemiological data on the incidence of metoclopramide-induced TD have varied. A real-world study using the MarketScan Research database (2011-2020) analyzed TD incidence in adults with at least 12 months of medical and pharmacy benefits, comparing rates among metoclopramide-treated gastroparesis patients, untreated patients, and the general population (https://pubmed.ncbi.nlm.nih.gov/41588797/). This study aimed to reassess TD risk based on more recent data, as older studies reported inconsistent incidence estimates ranging from 1% to 15%. Another review of the literature, including PubMed and Google Scholar searches, estimated the risk of TD from metoclopramide to be low, approximately 0.1% per 1000 patient-years, which is far below the previously estimated 1%-10% risk suggested in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). This review identified high-risk groups, including elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/).

Claim Valuation Factors for Reglan-Induced TD

From a settlement perspective, several factors influence claim valuation for patients alleging Reglan-induced TD. The adequacy of warnings is a central consideration: the FDA boxed warning explicitly states the risk of TD, the need for shortest treatment duration, and contraindication in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the warning also notes that metoclopramide may mask TD signs, potentially delaying diagnosis and treatment discontinuation. The timeline between exposure and documented harm is critical; the risk increases with longer treatment duration and higher cumulative doses, and immediate discontinuation is required upon development of signs or symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Claims may be stronger when patients were treated beyond the recommended 12-week maximum or when monitoring was inadequate. Additionally, the presence of known risk factors, such as advanced age, diabetes, or concurrent use of antipsychotics, may affect causation arguments and settlement value. The potentially irreversible nature of TD and its impact on quality of life are also key factors in assessing damages. In summary, Reglan carries a well-documented risk of TD, with regulatory warnings emphasizing limited treatment duration and monitoring. Epidemiological evidence suggests the absolute risk may be lower than previously thought, but certain populations remain at higher risk. Settlement considerations hinge on warning adequacy, exposure duration, and individual patient factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA boxed warning for Reglan regarding tardive dyskinesia?

The FDA boxed warning for Reglan states that the risk of developing tardive dyskinesia (TD) increases with the duration of treatment and total cumulative dosage. It emphasizes that the drug should be used for the shortest duration necessary, with periodic reassessment. For gastroesophageal reflux, the maximum treatment duration is 12 weeks; for diabetic gastroparesis, treatment beyond 12 weeks should be avoided unless longer use is unavoidable, with routine monitoring for TD signs and symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the key factors that influence the valuation of a Reglan TD claim?

Key factors include the adequacy of warnings (the FDA boxed warning), the duration and cumulative dose of Reglan exposure, the timeline between exposure and documented harm, the presence of known risk factors (e.g., advanced age, diabetes, concurrent antipsychotic use), and the severity and irreversibility of TD. Claims may be stronger when patients were treated beyond the recommended 12-week maximum or when monitoring was inadequate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What is the estimated risk of tardive dyskinesia from metoclopramide?

Estimates vary. A review of literature estimated the risk to be low, approximately 0.1% per 1000 patient-years, which is far below the previously estimated 1%-10% risk suggested in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). However, high-risk groups include elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.